A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Assessing Safety, Tolerability, and Efficacy of Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer’s Disease
Manuscript Number:
18-0759R3
Author(s):
Daniel L. Alkon, Jeffrey Benison, David Crockford, Martin R. Farlow, Elaine Grenier, Richard E. Thompson, Alan J. Tuchman, Lee-Jen Wei, Susanne Wilke
Disclosures
Daniel L. Alkon
Consulting Fees:
Consulting fees are $60,000 from NeuroDiagnostics LLC and $300,000 from Neurotrope Bioscience.
Equity:
260,000 shares and 130,000 options, both from Neurotrope Bioscience.
Jeffrey Benison
Equity:
I own shares of stock
David Crockford
Equity:
Employee stock options yet to be exercised.
No equity ownership.
Sponsors:
Neurotrope, Inc. as Vice President, Regulatory Affairs
Martin R. Farlow
Nothing to Disclose
Elaine Grenier
Equity:
Employee stock options
Sponsors:
I am the Executive Director of Clinical Operations for Neurotrope.
Richard E. Thompson
Consulting Fees:
I was paid by the sponsoring, Neurotrope Bioscience, for statistical consulting for this manuscript. Consulting fees for work on this manuscript totaled less than $20,000.
Alan J. Tuchman
Consulting Fees:
consulting fees from Neurotrope Inc.
Equity:
Oncolytics Biotech, 10 shares
Johnson & Johnson 1405 shares
Teva Pharmaceuticals 1000 shares
Lee-Jen Wei
Consulting Fees:
I have done statistical consultation for several drug companies and serve on the scientific advisory boards for three companies.
Equity:
For one of the scientific board, I do receive stock option.
Susanne Wilke
Equity:
I own stock and warrants at ~1% of NTRP
Patents/Royalties
I am on a patent for Veryex Pharmaceuticals, unrelated to the field of Alzheimer’s